Citation Impact
Citing Papers
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
2020 StandoutScienceNobel
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1
2001
Antibody-Dependent Enhancement of Virus Infection and Disease
2003
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
1990 Nature
Engineering precision nanoparticles for drug delivery
2020 Standout
Trametinib (GSK1120212) in the treatment of melanoma
2013
Ribosome-inactivating proteins from plants
1993
Somatic insertions and deletions shape the human antibody repertoire 1 1Edited by J. Karn
1999 StandoutNobel
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon
2000
Naturally occurring B-cell responses to breast cancer
2003
Structure of Dengue Virus
2002 Standout
Human Antibody Responses to HIV Type 1 Glycoprotein 41 Cloned in Phage Display Libraries Suggest Three Major Epitopes Are Recognized and Give Evidence for Conserved Antibody Motifs in Antigen Binding
1996
Increased Incorporation of Chimeric Human Immunodeficiency Virus Type 1 gp120 Proteins into Pr55gagVirus-like Particles by an Epstein–Barr Virus gp220/350-Derived Transmembrane Domain
1997
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
2009
Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
2010
Delivery technologies for cancer immunotherapy
2019 Standout
Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
2014
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
HIV as the cause of AIDS
1996 StandoutNobel
Summary Report: Workshop on the Potential Risks of Antibody-Dependent Enhancement in Human HIV Vaccine Trials
1993
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Management of Metastatic Melanoma 2005
2006
Clinical Pharmacokinetics of Interferons
1990
Genetics and pathogenesis of inflammatory bowel disease
2011 StandoutNature
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
2008 Standout
The repertoire of human germline vH sequences reveals about fifty groups of VH segments with different hypervariable loops
1992 StandoutNobel
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
Heterologous Epitope-Scaffold Prime∶Boosting Immuno-Focuses B Cell Responses to the HIV-1 gp41 2F5 Neutralization Determinant
2011 StandoutNobel
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Stimuli-responsive polymers and their applications in drug delivery
2009
Oxidative stress and apoptosis: a new treatment paradigm in cancer
2006
Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development
1994
Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
1991 StandoutNobel
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
1991
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1995 StandoutScience
Mouse plasmacytoma: an experimental model of human multiple myeloma.
2001
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection
2004 StandoutNobel
Molecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response.
1991
Fc receptors in antibody‐dependent enhancement of viral infections
2015
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 Standout
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
1996 StandoutNobel
Functional Role of Type I and Type II Interferons in Antiviral Defense
1994 StandoutScience
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner
2004 StandoutNobel
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
1993
Pathogenesis of human immunodeficiency virus infection
1993
Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.
1992
Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays
1998 Standout
Ischemic Cell Death in Brain Neurons
1999 Standout
Growth of Pseudotypes of Vesicular Stomatitis Virus with N-Tropic Murine Leukemia Virus Coats in Cells Resistant to N-Tropic Viruses
1973 StandoutNobel
Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases
1976 StandoutNobel
Phase I Trial of Imexon in Patients With Advanced Malignancy
2007
Fcγ Receptor-Mediated Suppression of Human Immunodeficiency Virus Type 1 Replication in Primary Human Macrophages
2003 StandoutNobel
Immunosuppressive retroviral peptides: Immunopathological implications for immunosuppressive influences of retroviral infections
1997
Ribonucleic Acud Polymerase in Virions of Newcastle Disease Virus: Comparison with the Vesicular Stomatitis Virus Polymerase
1971 StandoutNobel
Variable Constraints on the Principal Immunodominant Domain of the Transmembrane Glycoprotein of Human Immunodeficiency Virus Type 1
1999
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
1995 StandoutNobel
Cytokine therapeutics: lessons from interferonalpha.
1994
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
1998 StandoutScience
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
1993 StandoutNobel
Alanine Scanning of the Hepatitis C Virus Core Protein Reveals Numerous Residues Essential for Production of Infectious Virus
2007 StandoutNobel
Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages
1991
Effect of Prostaglandin E1 on Leukocyte Migration
1971
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160
1992 StandoutNobel
Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses
2005 StandoutNobel
Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations
1998
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
1992 Standout
Vaccination for Disease
1991 Science
Engineering Chemical Reactivity on Cell Surfaces Through Oligosaccharide Biosynthesis
1997 StandoutScienceNobel
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Works of E. Hersh being referenced
Sensitivity of Multiple Myeloma to Imexon in the Human Tumor Cloning Assay
1994
An open-label, multicenter, phase III trial of nab-paclitaxel (NP) versus dacarbazine (DTIC) in previously untreated patients (PTs) with metastatic malignant melanoma (MMM).
2010
Long-term engraftment of fresh human myeloma cells in SCID mice
1992
Leukocytic Mechanisms in Inflammation
1970
A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM)
2005
7003 ORAL Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial
2007
Analysis of Natural Killer Cell Cytotoxicity of Cancer Patients Treated With Recombinant lnterferon<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>
1983
7005 ORAL Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response
2007
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro
1990
Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine
2009
BCG as Adjuvant Immunotherapy for Neoplasia
1977
Treatment of hairy cell leukemia with recombinant alpha-interferon
1986
Isolation and characterization of a human monoclonal antibody which reacts with breast and colorectal carcinoma.
1991
In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
1991
Treatment of hairy cell leukemia with recombinant alpha-interferon
1986
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.
1990
Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
1995